On March 16, China Meheco Group Co.Ltd(600056) disclosed the risk warning announcement, saying that it had touched the abnormal fluctuation of stock trading for four times, and investors should pay attention to the trading risk of the secondary market.
According to the data, China Meheco Group Co.Ltd(600056) stock has increased the limit eight times in 11 trading days from March 2, 2022 to March 16, 2022, and the cumulative increase of stock price is 147.66%. As of the closing date of March 16, 2022, the median price earnings ratio (TTM) of the pharmaceutical circulation industry is 15.35 and the China Meheco Group Co.Ltd(600056) price earnings ratio (TTM) is 32.34, which is significantly higher than the price earnings ratio of the same industry.
China Meheco Group Co.Ltd(600056) said that the company signed an agreement with Pfizer Inc in March 9, 2022, and will be responsible for the commercial operation of Pfizer Inc COVID-19 virus treatment PAXLOVID in Chinese mainland market during the agreement period (2022).
On February 11, 2022, the State Drug Administration approved the import registration of the product with conditions. The product is a prescription drug. In March 15th, the national health and Health Committee released the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth). The product was included in the ninth edition of the treatment plan, but it has not yet entered the national health insurance. If it is included in the national medical insurance, it may have an impact on the sales price. The final use and sales of the product are affected by factors such as epidemic prevention and control, and there is great uncertainty. It is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance.
